Deployed transcranial electrical stimulation, without compromise.
Soterix Medical REMOTE Neuromodulation (ARTG Entry: 284637) is the only system with device, accessories, and software designed for deployed use. Safe transcranial Electrical Stimulation requires advanced systems designed for consistency and control. REMOTE Neuromodulation is the only system designed from the ground up to allow translation of clinical tES, including tDCS protocols, to diverse deployed environments, while maintaining medical standards.
Fail-safe and intelligent hand-held stimulators designed specifically for deployed use. Deliver only the right dose at the right time, with onboard compliance recording and ElectraRx compatibility.
SNAP Headgear accessories
The only head-gear that is simple to self-apply and guarantees accurate electrode placement. The only pre-saturated snap electrodes for tES in deployed environment.
ElectraRx integrates complete screening and assessments, tDCS dose management, and online digital therapeutics all in one place that can be accessed from anywhere.
Our Clinical TES systems are approved by the Australian Government's Therapeutic Goods Administration (TGA) ARTG Entry: 284637
Soterix Medical is committed to provide patients and physicians the most advanced, user-friendly, and effective neuromodulation treatments. Our clinical tDCS platforms are the only system to incorporate the latest, most robust technology. Unique electrode and head-gear snap-in technology make consistent and comfortable stimulation “a snap” for patient and care-givers.
Transcranial Direct Current Stimulation (tDCS) is a non-invasive procedure in which a device sends a small Direct Current (DC) across the scalp to modulate brain function.
tDCS mechanisms are considered to result from the ability of very weak DC currents to safely induce reversible changes in cortical plasticity. The induction of lasting changes in cortical excitability can, under some conditions, reversibly modify behavior and interact with normal learning. Such findings have driven a large number of studies examining whether tDCS might induce functionally significant changes in patients with a large variety of neurological and psychiatric disorders.
Delivering Transcranial Direct Current Stimulation Away From Clinic: Remotely Supervised tDCS. Shaw M, Pilloni G, Charvet LE. doi: 10.1093. PubMed PMID: 32074357. (2020)
Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression. Brunoni A.R., Moffa A.H., Sampaio-Junior B., Borrione L., Moreno M.L., Fernandes R.A., Veronezi B.P., Nogueira B.S., Aparicio L.V.M., Razza L.B., Chamorro R., Tort L.C., Fraguas R., Lotufo P.A., Gattaz W.F., Fregni F., Benseñor I.M.; ELECT-TDCS Investigators. (2017)
Transcranial direct current stimulation for the treatment of post-stroke depression: results from a randomised, sham-controlled, double-blinded trial. Valiengo L.C., Goulart A.C., de Oliveira J.F., Benseñor I.M., Lotufo P.A., Brunoni A.R. (2017)
Safety of Transcranial Direct Current Stimulation: Evidence Based Update Bikson M, Grossman P, Thomas C, Zannou AL, Jiang J, Adnan T, Mourdoukoutas AP, Kronberg G, Truong D, Boggio P, Brunoni AR, Charvet LE, et al. Brain Stimul. PubMed PMID: 27372845 (2016)
Concurrent cognitive control training augments the antidepressant efficacy of tDCS: a pilot study. Segrave R.A., Arnold S., Hoy K., Fitzgerald P.B. (2014)
The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial. Brunoni, A.R, Valiengo L., Baccaro A., Zanao T.A., de Oliveira J.F., Goulart A., Boggio P.S., Lotufo P.A., Bensenor I.M., Fregni,F. (2013)
Transcranial direct current stimulation for depression: 3-week, randomized, sham-controlled trial. Loo C.K., Alonzo A., Martin D., Mitchell P.B., Galvez V., Sachdev P. (2012)
A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression. Boggio P.S., Rigonatti S.P., Riberiro R.B., Myczkowski M.L., Nitsche M.A., Pascual-Leone A., Fregni F.(2008)
Soterix Medical REMOTE Neuromodulation systems are uniquely validated
Soterix Medical hardware and accessories for remote use is the only equipment designed and validated for the purpose. Other systems designed for use by professional and medical and research centers cannot be rigged for home use.
Soterix Medical REMOTE is supported by over a dozen clinical trials including the demonstration of tolerability, reproducibility, and compliance.
Delivering Transcranial Direct Current Stimulation Away From Clinic: Remotely Supervised tDCS. Mil Med. 2020
Telerehabilitation benefits patients with multiple sclerosis in an urban setting. J Telemed Telecare. 2019
Long term at-home treatment with transcranial direct current stimulation(tDCS) improves symptoms of cerebellar ataxia: a case report. J Neuroeng Rehabil. 2019
Introducing the thematic series on transcranial direct current stimulation (tDCS) for motor rehabilitation: on the way to optimal clinical use. J Neuroeng Rehabil. 2019
Generalizing remotely supervised tDCS: feasibility and benefit in Parkinson's disease. J Neuroeng Rehabil 2018
Remotely-supervised tDCS paired with cognitive training in Parkinson's disease: An open-label study. J Clin Neurosci 2018 Nov
Remotely-supervised tDCS for clinical trials: guidelines for technology and protocols. Front Syst Neurosci. 2015
The Soterix 1x1 CT is the most advanced and customizable system for true double-blinded trials.
Models: CT-tDCS and CT-tES
Double Blind: Customizable stimulation for true clinician and patient blinded studies for unbiased results
SMARTscan PLUS: Continuous indication of quality without compromising blind.
Integration: Combine with a 4X1 device to obtain 4x1 HD Stimulation while leveraging all the unique features of the 1x1 platform.
HD Software Compatible: Compatible with Soterix Medical’s revolutionary neurotargeting softwares HD-Targets and HD-Explore
Other Features: Customization options available